Overview

Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

Status:
Terminated

Trial end date:
2018-06-18

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if the combination product (URG101) is safe and effective versus its individual components (Heparin Sodium and Lidocaine Hydrochloride) for the treatment of Interstitial Cystitis/Bladder Pain Syndrome. The study is randomized and double-blinded such that neither the subject nor doctor will know which drug or placebo is received.

Phase:

Phase 2

Details

Lead Sponsor:

Urigen

Treatments:

Calcium heparin
Heparin
Lidocaine